Ann: Duke University and TALi Agreement, page-42

Don't forget it is Duke University who did clinical trial study of Akili Interactive's (an entity of PureTech Health, LSERTC) similar product targeting 8-12 year old children. Tali is for a younger group (3-7 years old). On 16/6/2020, Akili's product gained US FDA clearance as a prescription treatment for ADHD. What that means for Tali? Bright opportunity is one-step closer, Duke's expertise will speed up the launch of Tali products. Someone in this forum did a comparison between Akili and Tali (sorry mate I can't quickly pick up your nickname), those arguments are still valid. IMO, the approval of the first digital health product is a prove of concept, a good sign for Tali. I am exciting to see how Tali will be launched.

Anyone interested in Akili news, here is the link: https://www.thepharmaletter.com/article/puretech-unit-akili-gains-fda-clearance-of-endeavorrx-for-children-with-adhd